Dihuang Baoyuan Granules

Dihuang Baoyuan Granules is a Traditional Chinese Medicine (TCM) formulation developed by Beijing Supreme Life Pharmaceutical Technology for the treatment of type 2 diabetes mellitus. It is currently being evaluated in a Phase 2 clinical trial (NCT06575478) as part of a sequential therapy regimen alongside Fuling Yunhua Granules (Prescription A). The study targets patients with poor glycemic control despite diet and exercise interventions, exploring alternating treatment patterns (ABA and BAB sequences) over a 12-week period. While the specific herbal composition and molecular targets are not publicly disclosed, the formulation is designed to manage blood glucose levels within the framework of traditional Chinese medical practice for metabolic disorders.

Other names

Prescription B